Navigation Links
DuPont Leaders Brief Investors on Agriculture Businesses
Date:8/19/2007

DuPont Science Addressing Increased Demand for Food, Feed, Fuel, Materials

DES MOINES, Iowa, Aug. 15 /PRNewswire-FirstCall/ -- DuPont (NYSE: DD) Chairman and CEO Charles O. Holliday, Jr., Executive Vice President & Chief Innovation Officer Thomas M. Connelly, and Group Vice President -- DuPont Agriculture & Nutrition J. Erik Fyrwald today updated investors on DuPont businesses serving the agriculture and biofuels markets.

"Global population growth, rising income and demand for biofuels is driving increased demand for agricultural outputs," Holliday said at the DuPont Global Agriculture Investors' Day. "DuPont is uniquely positioned to meet that challenge due to our multi-discipline science, ability to leverage that science across different industries, and our broad market access and global reach."

Connelly added, "The synergies among agricultural biotechnology, biofuels and biomaterials are creating potential game-changing solutions to the global challenges we face today and significant growth opportunities for DuPont."

The company's core competencies to drive innovation across a number of biotechnology markets include cell biology/physiology, molecular biology (gene discovery, expression and optimization), genomics, proteomics, biochemistry and metabolic engineering.

Noting that DuPont is using biotechnology to deliver advanced plant genetics along with chemistry to improve productivity, quality and yield, Fyrwald reviewed the platform's top pipeline candidates.

"We are advancing a rich pipeline of new products to enhance yield and nutrition," he said, referencing top-performing insect resistant corn, Rynaxypyr(TM) low-dosage insecticide, fungal resistant corn, Optimum(TM) GAT(TM) dual herbicide tolerance and healthier soybean oil.

To more strongly position itself for attractive agricultural markets, DuPont announced last year that it was investing $100 million in savings from a restructuring into its crop genetics research and seed sales and marketing.

"The growth fundamentals in seed markets around the world are outstanding," said Fyrwald. "As a result, we are accelerating our growth investments at a faster rate than the savings from our previously announced restructuring plan."

Approximately $100 million in growth investments will be made in 2007. The investments are targeted at accelerating new product launches, increasing the rate of genetic gain, expanding capacity for plant biotechnology discovery and development, increased sales coverage, and more aggressive promotions. With regard to savings from the restructure program, Fyrwald said DuPont Agriculture & Nutrition will generate savings of approximately $20 million of the $100 million target late in 2007, another $40 million in savings in 2008, and the remaining $40 million in savings in 2009.

Fyrwald noted that for the year 2007, he expects the DuPont Agriculture & Nutrition platform to deliver about 10 percent revenue growth and 20 percent pretax operating income (PTOI) growth before accounting for the accelerated growth investments. Including the investments, PTOI growth would be about 10 percent, compared to a compound annual average growth rate of 14 percent since 2001.

DuPont reaffirmed its outlook for 2007 full-year earnings per share of about $3.15, excluding a $0.06 per share charge for significant items in the first quarter 2007.

A replay of today's presentation and the question and answer session can be found at the Investor Center of the company's website at http://www.dupont.com. DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

The DuPont Oval Logo, DuPont(TM), The miracles of science(TM), Rynaxypyr(TM) and Optimum(TM) GAT(TM) are registered trademarks or trademarks of DuPont or its affiliates.


'/>"/>
SOURCE DuPont

Copyright©2007 PR Newswire.

Related biology technology :

1. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
2. CIO Leadership Series: Logothetis likes CIOs evolving role
3. CIO Leadership Series: Phil Loftus, Aurora Health Care
4. CIO Leadership Series: Deb Rislow, Gundersen Lutheran
5. Patent ruling doesnt tarnish Wisconsins stem cell leadership
6. CIO Leadership Series: Judy Lemke, Schneider National
7. CIO Leadership Series: Tanya Townsend, Saint Clares Hospital
8. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
9. CIO Leadership Series: Rick Davidson, Manpower
10. CIO Leadership Series: Mike Sauk, UW Hospital and Clinics
11. CIO Leadership Series: Ed Meachen, University of Wisconsin System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, ... with peritoneal dialysis, announced today that it has published the result of its ... Peritoneal Dialysis International (PDI), the official Journal of the International Society for ...
(Date:2/20/2017)... 20, 2017  Atrius Health and IBM (NYSE: ... agreement to develop a cloud based service designed ... holistic view of the multiple influences on an ... could be designed to support shared decision making ... innovative nonprofit healthcare organization with 875 physicians caring ...
(Date:2/18/2017)... Heights, IL (PRWEB) , ... February 17, 2017 ... ... for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & ... Palms Convention Center in Orlando, Fla. , The combined scientific sessions ...
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):